Arog Pharmaceuticals
Arog is a private Dallas biotech developing crenolanib, a FLT3 and PDGFR kinase inhibitor, through phase 3 trials in FLT3-mutant acute myeloid leukaemia and gastrointestinal stromal tumours.
Overview
Arog Pharmaceuticals, based in Dallas, Texas, licensed crenolanib from Pfizer and has taken it into phase 3 trials in newly diagnosed and relapsed FLT3-mutated acute myeloid leukaemia and in PDGFRA D842V-mutant gastrointestinal stromal tumours, all registered on ClinicalTrials.gov under Arog as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCyclacel Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyDelta-Fly Pharma
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.